Preparation and application of mycoplasma pneumoniae recombinant antigen

Abstract

The invention discloses a technical solution of collecting a sequence of a mycoplasma pneumoniae gene from Genbank, establishing gene data of mycoplasma pneumoniae, and analyzing the gene data throughcomputer software to obtain a segment which has detection activity of mycoplasma pneumoniae adhesion protein P1 (GenBank: AF286371.1) and adhesion protein P30 (GenBank: EF614306.1), and connecting 252nd-355th amino acids (P1A), the 898th-953rd amino acids (P1B), 1274th-1362nd amino acids (P1C), 1589th-1627th amino acids (P1D) of the P1 gene, and a P30 fragment of174th-274th amino acid of the mycoplasma pneumoniae adhesion proteinP30 in series through connecting peptides GSGSGS, wherein the sequence of connections in series is sequentially a P1A fragment-a first connecting peptide-a P1B fragment-a second connecting peptide-P1C-a third connecting peptide-P1C-a fourth connecting peptide-P1D-a fifth connecting peptide-a P30 fragment from a C terminal to an N terminal, and the corresponding nucleic acid sequence is obtained by a chemical synthesis method.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to the preparation and application of a Mycoplasma pneumoniae recombinant antigen. Background technique [0002] Mycoplasma pneumoniae is one of the main pathogens that cause primary atypical pneumonia in humans. It occurs frequently in the cold seasons of autumn and winter. Teenagers are susceptible groups and are mainly transmitted through droplets. Clinically, the main symptoms are respiratory symptoms, sore throat, fever, cough, low-grade fever, etc., and cough is the most prominent manifestation. In addition to respiratory symptoms, patients with mycoplasma pneumonia are accompanied by lesions in the gastrointestinal system, blood system, nervous system and cardiovascular system, which has attracted widespread attention. [0003] Currently, the diagnostic methods of Mycoplasma pneumoniae clinically used are isolation and cultivation of main pathogens, indirect immunoflu...

AI Technical Summary

Problems solved by technology

If the detection of IgM antibody is negative, it cannot determine non-mycoplasma pneumoniae infection, and IgG antibody detection is required; at present, the incidence of mycoplasma pneumoniae in my country is on the rise, especially among adolescents, and the current etiological and serological detection methods The operation is complicated and time-consuming, which is not conducive to timely treatment of patients. Among the current serological detection methods, natural antigens are used the most. The production process of natural antigens is cumbersome and expensive, and increases the infection probability of experimental operators. The development of recombinant MP antigen with strong antigenicity and good sensitivity also lays the foundation for the development of rapid and accurate detection of Mycoplasma pneumoniae IgM and IgG antibody kits. For this reason, we provide a preparation and application of Mycoplasma pneumoniae recombinant antigen. Solve the problems raised in the above-mentioned background technology

Images